Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Dyslipidemia

  Free Subscription


05.02.2018

11 Atheroscler Suppl
6 Atherosclerosis
2 Lancet Diabetes Endocrinol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Atheroscler Suppl

  1. SCHATZ U, Tselmin S, Muller G, Julius U, et al
    Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study.
    Atheroscler Suppl. 2017;30:246-252.
    PubMed     Text format     Abstract available

  2. BLAHA V, Blaha M, Solichova D, Krcmova LK, et al
    Antioxidant defense system in familial hypercholesterolemia and the effects of lipoprotein apheresis.
    Atheroscler Suppl. 2017;30:159-165.
    PubMed     Text format     Abstract available

  3. POLLER WC, Berger A, Dreger H, Morgera S, et al
    Lipoprotein apheresis in patients with peripheral artery disease and lipoprotein(a)-hyperlipoproteinemia: 2-year follow-up of a prospective single center study.
    Atheroscler Suppl. 2017;30:174-179.
    PubMed     Text format     Abstract available

  4. HOHENSTEIN B, Julius U, Lansberg P, Jaeger B, et al
    Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.
    Atheroscler Suppl. 2017;30:180-186.
    PubMed     Text format     Abstract available

  5. EZHOV MV, Afanasieva OI, Il'ina LN, Safarova MS, et al
    Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis.
    Atheroscler Suppl. 2017;30:187-192.
    PubMed     Text format     Abstract available

  6. SCHMOCKER C, Kassner U, Ostermann AI, Kiesler S, et al
    Effect of different lipid apheresis methods on plasma polyunsaturated fatty acids.
    Atheroscler Suppl. 2017;30:193-199.
    PubMed     Text format     Abstract available

  7. STEFANUTTI C, Mazza F, Pasqualetti D, Di Giacomo S, et al
    Lipoprotein apheresis downregulates IL-1alpha, IL-6 and TNF-alpha mRNA expression in severe dyslipidaemia.
    Atheroscler Suppl. 2017;30:200-208.
    PubMed     Text format     Abstract available

  8. TSELMIN S, Muller G, Schatz U, Julius U, et al
    Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia.
    Atheroscler Suppl. 2017;30:209-216.
    PubMed     Text format     Abstract available

  9. RAMLOW W, Roseler E, Heigl F, Spitthover R, et al
    Efficacy of lipid reduction with DALI and MONET.
    Atheroscler Suppl. 2017;30:217-224.
    PubMed     Text format     Abstract available

  10. KOZIK-JAROMIN J, Roseler E, Heigl F, Spitthover R, et al
    Safety aspects of lipidapheresis using DALI and MONET - Multicenter observational study.
    Atheroscler Suppl. 2017;30:225-231.
    PubMed     Text format     Abstract available

  11. PAPIN J, Brennand A, Arbore G, Hohenstein B, et al
    Dysregulation of the CD4(+) T cells lineage differentiation in dyslipidemic patients and impact of lipoprotein-apheresis treatment: A case study.
    Atheroscler Suppl. 2017;30:238-245.
    PubMed     Text format     Abstract available


    Atherosclerosis

  12. CHO I, O Hartaigh B, Gransar H, Valenti V, et al
    Prognostic implications of coronary artery calcium in the absence of coronary artery luminal narrowing.
    Atherosclerosis. 2017;262:185-190.
    PubMed     Text format     Abstract available

  13. BOURBON M, Alves AC, Alonso R, Mata N, et al
    Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: The SAFEHEART registry.
    Atherosclerosis. 2017;262:8-13.
    PubMed     Text format     Abstract available

  14. YANG ZH, Gordon SM, Sviridov D, Wang S, et al
    Dietary supplementation with long-chain monounsaturated fatty acid isomers decreases atherosclerosis and alters lipoprotein proteomes in LDLr(-/-) mice.
    Atherosclerosis. 2017;262:31-38.
    PubMed     Text format     Abstract available

  15. BUONUOMO PS, Iughetti L, Pisciotta L, Rabacchi C, et al
    Timely diagnosis of sitosterolemia by next generation sequencing in two children with severe hypercholesterolemia.
    Atherosclerosis. 2017;262:71-77.
    PubMed     Text format     Abstract available

  16. MASANA L, Plana N, Perez-Calahorra S, Ibarretxe D, et al
    How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Atherosclerosis. 2017;262:107-112.
    PubMed     Text format     Abstract available

  17. STEINHAGEN-THIESSEN E, Stroes E, Soran H, Johnson C, et al
    The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency.
    Atherosclerosis. 2017;262:146-153.
    PubMed     Text format     Abstract available


    Lancet Diabetes Endocrinol

  18. LANGSTED A, Kamstrup PR, Benn M, Tybjaerg-Hansen A, et al
    High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study.
    Lancet Diabetes Endocrinol. 2016 May 12. pii: S2213-8587(16)30042.
    PubMed     Text format     Abstract available

  19. AJUFO E, Rader DJ
    Recent advances in the pharmacological management of hypercholesterolaemia.
    Lancet Diabetes Endocrinol. 2016 Mar 21. pii: S2213-8587(16)00074.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dyslipidemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: